Latest Research, Industry, Medical and Scientific News
Rinovum Women’s Health, the makers of the successful Stork® products for at-home conception has debuted a breakthrough reusable device, clinically proven to treat light bladder leaks that does not require a prescription, impacting the more than 15 million women in the U.S. who suffer from the embarrassing issue. The revolutionary product Revive™ is an FDA-cleared urethral support device designed to empower women and help them to take charge of their health by kicking stress urinary incontinence (SUI) to the curb. After successfully growing The Stork ®OTC, the first conception aid sold over-the-counter, Rinovum Women’s Health has made Revive available in nearly 5,000 retail locations nationwide and growing. Read more.
Source: BioSpace, June 24, 2019
“OMG. I just free’d myself!” Today, 20 million women in America will rewrite that whispered, uncomfortable admission of bladder weakness1 into a declarative, celebratory shout thanks to INNOVO®. As the first-in-class wearable, non-invasive solution for Stress Urinary Incontinence (SUI), INNOVO has the potential to positively impact the lives of one in three women.2 These women will now be able to laugh louder, exercise harder and even sneeze with ease. The INNOVO thigh-length, elasticized therapeutic shorts are outfitted with eight electrodes sewn in a crisscross formation across the pelvic region. When activated via its attached hand-held controller, INNOVO delivers a series of pelvic stimulations equivalent to Kegel exercises for strengthening the pelvic floor. Read more.
Source: PRNewswire, June 5, 2019
Urinary tract infections are one of the indignities many women face as they age. One reason why is because their bladder walls can be invaded by several species of bacteria, a new study finds. Urinary tract infections, or UTIs, are among the most common type of bacterial infections in women, accounting for nearly 25% of all infections. UTI recurrence rates can range from 16%-36% in younger women to 55% in postmenopausal women. In the new study, researchers at University of Texas Southwestern (UTSW) in Dallas analyzed bacteria in bladder biopsies from 14 postmenopausal women with recurrent UTI. The investigators found that, in these patients, several species of bacteria can get inside the bladder’s surface area. Read more.
Source: HealthDay News, May 20, 2019
Domtar Corporation today announced that its Personal Care Division, a leading manufacturer in the disposable incontinence product category for over 35 years, launched their most absorbent and highest performing product line in the Attends® family. The new Attends® Premier product line of briefs, underwear and a premium underpad, has launched to the North American Healthcare market both in-store and online. Read more.
Source: Business Wire, May 20, 2019
If urinary incontinence is affecting your life, please help The Simon Foundation for Continence understand your challenges and give your input to help design a new program we are creating. The study focus groups are 90-minutes long and will take place in June 2019. Current locations are: Evanston, Chicago and Forest Park, Illinois.Continue reading
Today, the American Urological Association (AUA), a leading global urology association, and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), released a new clinical guideline on the treatment of urinary incontinence after prostate treatment (IPT). IPT is one of the few urologic conditions that is iatrongenic, and therefore predictable, and often preventable. A condition that tends to cause a high degree of patient distress, IPT has gained visibility over the past several years due to the use of surgery to treat prostate cancer, as well as the proliferation of men’s continence products available to the lay public. Read more.
Source: PRNewswire, May 3, 2019